InspireMD NSPR 深 沪
已收盘 11-07 16:00:00 美东时间
1.81
-0.150
-7.65%
华盛通- 最 高2.0399
- 今 开1.96
- 成交量 88.03万股
- 最 低 1.7701
- 昨 收 1.96
- 总市值 7551.45万
- 52周最高 3.798
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.7701
- 委 比 52.83%
- 总股本 4172.07万
- 历史最高 27890625.00
- 量 比 9.34
- 振 幅 13.77%
- 历史最低 0.806
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InspireMD Reports Record Q3 Revenue with U.S. Launch
InspireMD ( ($NSPR) ) has provided an update. On November 4, 2025, InspireMD re...
11-05 05:53
InspireMD GAAP EPS of -$0.17
InspireMD press release (NSPR): Q3 GAAP EPS of -$0.17. As of September 30, 2025, cash and cash equivalents and marketable securities were $63.4 million compared to $34.6 million as of December 31, 202...
11-04 20:29
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
InspireMD Reports Third Quarter 2025 Financial Results
Miami, Nov. 4, 2025 – InspireMD, Inc. reported strong Q3 2025 results with a 39% revenue increase to $2.5 million, driven by the successful U.S. launch of its CGuard Prime carotid stent system. Despite a 57% rise in operating expenses to $13.9 million and a net loss of $12.7 million, the company’s cash reserves grew to $63.4 million following a $58 million equity raise. Key highlights include over 100 U.S. procedures, leadership team expansions, ...
11-04 12:00
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
InspireMD, Inc. announced the appointment of Dr. Peter A. Soukas as Chief Medical Officer to lead its clinical and medical organization. Dr. Soukas, a renowned expert in carotid intervention and peripheral vascular disease, will help advance the launch of the CGuard Prime stent system in the U.S. market. His extensive experience, including leadership in clinical trials and research, will contribute to improving patient outcomes and advancing inno...
11-03 12:30
Inspirato Reaffirms Independent Strategy, Highlights Recent Achievements and Its Focus on Long-Term Shareholder Value
Inspirato Incorporated has rejected recent acquisition offers, opting to maintain independence. Over the past 14 months, the company has reduced overhead, relaunched its Inspirato Pass, enhanced luxury travel experiences, and achieved profitability. Focused on maximizing shareholder value, it will only pursue transactions aligned with its mission. Inspirato is also exploring financing options to support growth as an independent entity.
09-29 13:00
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD announced inducement grants of 88,324 restricted shares to five new non-executive employees outside its 2021 Equity Incentive Plan under the 2024 Inducement Plan. The grants vest over three years, with one-third vesting annually on the first, second, and third anniversaries, contingent on continued employment.
09-25 20:05
Inspirato and Buyerlink Announce Mutual Decision to End Merger Agreement
Inspirato Incorporated and Buyerlink have mutually agreed to terminate their previously announced merger agreement, with Inspirato continuing to operate independently. The decision reflects the company's strengthened operational momentum, member engagement, and leadership in luxury travel. Inspirato's board concluded that remaining independent aligns with maximizing shareholder value while fostering brand growth and member experience. The company...
09-15 13:00
InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference
InspireMD, Inc. announced plans to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 10:00am ET. The presentation will cover the CGuard® Prime carotid stent system for stroke prevention. A live audio webcast and replay will be available on the company’s website.
08-27 13:00
Inspire Medical Systems, Inc. Announces Departure of Chief Financial Officer
Inspire Medical Systems announced that Chief Financial Officer Rick Buchholz will step down effective December 31, 2025, to pursue other opportunities. He will serve as a financial advisor until February 28, 2026, to ensure a smooth transition. Buchholz has significantly contributed to the company's growth since 2014, including revenue growth from $4 million to over $800 million and navigating challenges such as the COVID-19 pandemic. The company...
08-26 20:30
